JP2001504087A - Ltb4―アンタゴニスト活性を有するベンズアミド誘導体及びその医薬としての使用 - Google Patents
Ltb4―アンタゴニスト活性を有するベンズアミド誘導体及びその医薬としての使用Info
- Publication number
- JP2001504087A JP2001504087A JP51324398A JP51324398A JP2001504087A JP 2001504087 A JP2001504087 A JP 2001504087A JP 51324398 A JP51324398 A JP 51324398A JP 51324398 A JP51324398 A JP 51324398A JP 2001504087 A JP2001504087 A JP 2001504087A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- hydrogen
- alkyl
- branched
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
- C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Pyrane Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 一般式1のベンズアミド誘導体。 式中、 Aは −OC2-C4−アルキレン−O−又は−C1-C3−アルキレン−O−を表わし ; R1は 分岐鎖又は直鎖のC1-C6−アルキル、分岐鎖又は直鎖のC3−C6−アル ケニル好ましくはアリル又はF、Cl、Br、Iを表わし; R2は 水素、分岐鎖又は直鎖のC1-C6−アルキル、分岐鎖又は直鎖のC3-C6− アルケニル、好ましくはアリル又はF、Cl、Br、Iを表わし; R3及びR4は同一でも異なっていてもよく、水素、分岐鎖又は直鎖のC1-C6− アルキル、分岐鎖又は直鎖のC3-C6−アルケニル、好ましくはアリル、C1-C6−ア ルコキシ、(C1-C4−アルキル)OC(O)O−、OH、CF3又は一緒になって、全体又は部 分的に共役していてもよく、かつ酸素、硫黄又は窒素からなる群から選択される 互いに同一でも異なっていてもよい一種以上のヘテロ原子を任意に含み、任意に OH、C1-C4−アルコキシ又はC1-C4−アルキルにより置換されていてもよい、単核 又は二核の縮合環システムを表わし; R5 水素、アリール、好ましくはフェニル、−O フェニル、−CR7R8フェ ニル、−CO フェニル、SO2−フェニル、−CH(OH)フェニルを表わし、前記化合物 においてフェニル環はOH、C1-C4−アルコキシ又は−C(O)NR9R10により置換され ていてもよい; R6は 水素、C1-C6−アルコキシカルボニル、(C1-C5−アルキル)−カルボニ ル又は−C(O)−O−(C1-C6−アルキレン)−NR11R12を表わし; R7及びR8は同じでも異なっていてもよく、水素又は分岐鎖又は直鎖のC1-C8 −アルキルを表わし; R9及びR10は同じでも異なっていてもよく、各々独立に水素、分岐鎖又は直 鎖のC1-C8−アルキルを表わし; R11及びR12は同じでも異なっていてもよく、各々独立に水素、分岐鎖又は直 鎖のC1-C8−アルキルを表わし; 任意に光学異性体、エナンチオマー混合物又はラセミ体であってもよく、及 び遊離塩基又は薬学的に許容される酸の相当する酸付加塩であってもよい。 2. 請求項1に記載の一般式1の化合物; 式中、 Aは −OCH2CH2O−、−CH2O−、−CH2CH2CH2O−を表わし; R1は 分岐鎖又は直鎖のC1-C5−アルキル又はアリルを表わし; R2 は水素を表わし; R3 は水素、C1-C6−アルキル、−OCH3、C2H5OC(O)O−、OH、Cl、F、CF3を 表わし; R4は 水素、−OCH3、OHを表わし; R3及びR4は一緒になって縮合ベンゼン環、3,4−ジヒドロクマリンシステム 又は1,3−ジオキソランシステムを表わし、前記化合 物はOH、C1-C3−アルキル、OCH3により置換されていてもよい; R5は 水素、フェニル、O フェニル、−CR7R8フェニル、前記化合物におい てフェニル環はOH、OCH3又は−C(O)NR9R10により置換されていてもよい; R6は 水素又はC1-C4−アルコキシカルボニル又は−C(O)−O−(CH2)2−N(C2 H5)2を表わし; R7及びR8は同一でも異なっていてもよく、各々独立に水素、CH3又はCF3を表 わし; R9及びR10は同一も異なっていてもよく、水素または分岐鎖又は直鎖のC1-C8 −アルキルを表わす。 3. 一般式2のアミドオキシムを既知の方法で還元することを特徴とする、一般 式1の化合物の製造方法。 式中、R1〜R5及びAは請求項1で定義した通りである。 4. 該還元を触媒により、好ましくはラネーニッケル存在下に行うことを特徴と する、請求項2に記載の方法。 5. アミドオキシムの接触還元を低級アルコール、好ましくはメタノール中で行 うことを特徴とする請求項3又は4に記載の方法。 6. 以下の化合物をアンモニアと反応させることを特徴とする一般式1の化合物 を製造する方法; (式中、R1〜R5及びA式中、R1〜R5及びAは請求項1に定義される通りである) 。 7. 有機溶媒中で、約0℃〜反応混合物の沸点温度の範囲の温度、好ましくは室 温〜約100℃又はより低い場合には沸点において、反応を行うことを特徴とする 、請求項6に記載の方法。 8. 反応を極性溶媒中、好ましくはメタノール、エタノール又はプロパノール中 で行うことを特徴とする、請求項6又は7に記載の方法。 9. 一般式1の化合物を製造する方法であって、一般式4のフェノールを式5の 化合物と非極性溶媒中において反応させることを特徴とする上記方法; 式中、R1、R2及びR6は請求項1に定義されている通りであり、 式中、A、R3、R4及びR5は請求項1に定義されている通りであり、及びL1は 又は離核性の脱離基、好ましくはハロゲン原子又はスルホン酸基を表わす。 10.該溶媒がジメチルホルムアミド、アセトニトリル又はアルコール、好ましく はメタノール、エタノール又はプロパノールであることを特徴とする、請求項9 に記載の方法。 11.該反応を塩基存在下、好ましくはアルカリ金属又はアルカリ土類金属の炭酸 塩、金属水酸化物、又は金属水素化物存在下に行うことを特徴とする、請求項9 又は10記載の方法。 12.該反応を0℃から反応混合物の沸点の範囲の温度、好ましくは0〜140℃の温 度範囲において反応を行うことを特徴とする請求項9〜11のいずれか一項に記載 の方法。 13.一般式1の化合物の製造方法であって、一般式6のアミジンを一般式7の化 合物と反応させることを特徴とする上記方法; 式中、R1〜R5及びAは請求項1に定義される通りであり、 L2−R6' (7) 式中、R6'はC1-C6−アルコキシカルボニル又はC1-C6−アシルを表わし、及 びL2は離核性の脱離基、好ましくは塩素、臭素又はアシロキシを表わす。 14.該反応を極性溶媒中において行うことを特徴とする請求項13に記載の方法。 15.該溶媒がテトラヒドロフラン、メチレンクロライド、クロロホルム又はジメ チルホルムアミドであることを特徴とする、請求項14に記載の方法。 16.該反応を無機塩基存在下、好ましくは炭酸ナトリウム、炭酸カリウム又は水 酸化ナトリウム水溶液、又は4級有機塩基、好ましくはトリエチルアミン、N− エチル−ジイソプロピルアミン、N−メチルモルホリン又はピリジン存在下にお いて行うことを特徴とする、請求項14又は15に記載の方法。 17.該反応を−30〜100℃、好ましくは−10〜80℃の温度範囲にて行うことを特 徴とする請求項14〜16のいずれか一項に記載の方法。 18.請求項1又は2のいずれか一項に記載の化合物又はその酸付加塩及び補形剤 および/またはキャリアーを含む医薬組成物。 19.請求項1又は2のいずれか一項に記載の化合物の医薬組成物としての使用。 20.LTB4−アンタゴニスト様活性を有する、請求項19に記載の化合物の医薬組成 物としての使用。 21.関節炎、喘息、慢性閉塞性肺疾患(例えば慢性気管支炎)、乾癬、潰瘍性大腸 炎、非ステロイド性抗炎症薬により誘導された胃疾患又は腸疾患、嚢胞性繊維症 、アルツハイマー症、ショック、再灌流障害/虚血(reperfusion damage/ischaem ia)、アテローム性大動脈症及び多発性硬化症の治療用薬剤の製造のための、一 般式1の化合物、その立体異性体又はその酸付加塩の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19636689A DE19636689A1 (de) | 1996-09-10 | 1996-09-10 | Neue Benzamidinderivate |
DE19636689.5 | 1996-09-10 | ||
PCT/EP1997/004921 WO1998011062A1 (de) | 1996-09-10 | 1997-09-09 | Benzamidinderivate und ihre verwendung als arzneimittel mit ltb4-antagonistischer wirkung |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008107036A Division JP4288299B2 (ja) | 1996-09-10 | 2008-04-16 | Ltb4−アンタゴニスト活性を有するベンズアミジン誘導体及びその医薬としての使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001504087A true JP2001504087A (ja) | 2001-03-27 |
JP4150427B2 JP4150427B2 (ja) | 2008-09-17 |
Family
ID=7805125
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51324398A Expired - Fee Related JP4150427B2 (ja) | 1996-09-10 | 1997-09-09 | Ltb4―アンタゴニスト活性を有するベンズアミジン誘導体及びその医薬としての使用 |
JP2008107036A Expired - Fee Related JP4288299B2 (ja) | 1996-09-10 | 2008-04-16 | Ltb4−アンタゴニスト活性を有するベンズアミジン誘導体及びその医薬としての使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008107036A Expired - Fee Related JP4288299B2 (ja) | 1996-09-10 | 2008-04-16 | Ltb4−アンタゴニスト活性を有するベンズアミジン誘導体及びその医薬としての使用 |
Country Status (31)
Country | Link |
---|---|
US (2) | US6197824B1 (ja) |
EP (2) | EP0929516B1 (ja) |
JP (2) | JP4150427B2 (ja) |
KR (1) | KR20000036005A (ja) |
CN (1) | CN1104412C (ja) |
AR (1) | AR009741A1 (ja) |
AT (2) | ATE224363T1 (ja) |
AU (1) | AU727900B2 (ja) |
BG (1) | BG63938B1 (ja) |
BR (1) | BR9712816A (ja) |
CA (1) | CA2262566C (ja) |
CO (1) | CO4900032A1 (ja) |
CZ (1) | CZ297252B6 (ja) |
DE (3) | DE19636689A1 (ja) |
DK (1) | DK0929516T3 (ja) |
EA (1) | EA003245B1 (ja) |
EE (1) | EE04431B1 (ja) |
ES (1) | ES2184131T3 (ja) |
HK (1) | HK1020564A1 (ja) |
HU (1) | HUP9904367A3 (ja) |
IL (1) | IL128144A (ja) |
NO (1) | NO312239B1 (ja) |
NZ (1) | NZ334895A (ja) |
PL (1) | PL188012B1 (ja) |
PT (1) | PT929516E (ja) |
SK (1) | SK282432B6 (ja) |
TR (1) | TR199900501T2 (ja) |
TW (1) | TW378200B (ja) |
UA (1) | UA60315C2 (ja) |
WO (1) | WO1998011062A1 (ja) |
ZA (1) | ZA978045B (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000035858A1 (en) * | 1998-12-14 | 2000-06-22 | F. Hoffmann-La Roche Ag | Phenylglycine derivatives |
DE19948428A1 (de) * | 1999-10-07 | 2001-04-12 | Boehringer Ingelheim Pharma | Neuer LTB¶4¶-Antagonist, Verfahren zu dessen Herstellung und dessen Verwendung als Arzneimittel |
US6291531B1 (en) * | 1999-10-07 | 2001-09-18 | Boehringer Ingelheim Pharma Kg | LTB4 antagonist, processes for the preparation thereof and its use as a pharmaceutical composition |
US6528491B2 (en) | 2000-10-24 | 2003-03-04 | Boehringer Ingelheim Pharma Kg | Pyranoside derivatives |
US6489359B2 (en) | 2000-10-24 | 2002-12-03 | Boehringer Ingelheim Pharma Kg | Sulphoxybenzamides |
DE10052333A1 (de) * | 2000-10-24 | 2002-05-02 | Boehringer Ingelheim Pharma | Neue Sulfooxybenzamide |
DE10052658A1 (de) * | 2000-10-24 | 2002-05-02 | Boehringer Ingelheim Pharma | Neue Pyranosidderivate |
US6608054B2 (en) * | 2001-03-20 | 2003-08-19 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics and endothelin antagonists |
US7776315B2 (en) * | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
AU4239302A (en) * | 2001-06-28 | 2003-01-02 | Pfizer Products Inc. | Benzoic acid substituted benzopyrans for the treatment of atherosclerosis |
US20030119901A1 (en) * | 2001-07-14 | 2003-06-26 | Boehringer Ingelheim Pharma Kg | Pharmaceutical formulation containing an LTB4 antagonist |
ES2244821T3 (es) * | 2001-07-14 | 2005-12-16 | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG | Formulacion de medicamento que contiene un antagonista de ltba y un agente humectante. |
IL160208A0 (en) * | 2001-08-31 | 2004-07-25 | Neurochem Int Ltd | Amidine derivatives for treating amyloidosis |
DE10213350A1 (de) * | 2002-03-26 | 2003-10-16 | Boehringer Ingelheim Pharma | Verwendung von LTB¶4¶Antagonisten in der Tiermedizin |
US6921752B2 (en) * | 2002-03-26 | 2005-07-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of LTB4 antagonists in veterinary medicine |
RS20050390A (en) * | 2002-11-26 | 2008-04-04 | Boehringer Ingelheim Pharma Gmbh. & Co.Kg., | Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox 1/2 inhibitor |
US7262223B2 (en) * | 2004-01-23 | 2007-08-28 | Neurochem (International) Limited | Amidine derivatives for treating amyloidosis |
US20080200526A1 (en) * | 2004-07-05 | 2008-08-21 | Jin Soo Lee | Composition for the Prevention and Treatment of Allergic Inflammatory Disease |
KR20060017929A (ko) * | 2004-08-04 | 2006-02-28 | 동화약품공업주식회사 | 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물 |
US8679288B2 (en) * | 2008-06-09 | 2014-03-25 | Lam Research Corporation | Showerhead electrode assemblies for plasma processing apparatuses |
CN106831611B (zh) * | 2017-01-23 | 2019-06-21 | 北京化工大学 | 一种偕胺肟类化合物及其在制备抑制癌细胞增殖药的应用 |
AU2018266393A1 (en) | 2017-05-12 | 2019-12-19 | Riken | Class A GPCR-binding compound modifier |
EP3856234A4 (en) * | 2018-09-24 | 2022-07-06 | The University of British Columbia | MODULATION OF GRANZYME K ACTIVITY IN THE TREATMENT OF SKIN CONDITIONS |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4102024A1 (de) | 1991-01-24 | 1992-07-30 | Thomae Gmbh Dr K | Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
US5246965A (en) | 1991-06-11 | 1993-09-21 | Ciba-Geigy | Arylethers, their manufacture and methods of treatment |
EP0518818A3 (en) * | 1991-06-11 | 1993-04-28 | Ciba-Geigy Ag | Arylethers, their manufacture and use as medicament |
HU216191B (hu) * | 1992-02-05 | 1999-05-28 | Boehringer Ingelheim Kg | Eljárás új amidinszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
DE4219158A1 (de) * | 1992-06-11 | 1993-12-16 | Thomae Gmbh Dr K | Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
DE4424714A1 (de) * | 1994-07-13 | 1996-01-18 | Boehringer Ingelheim Kg | Neue chemische Verbindung, ihre Herstellung und ihre Verwendung als Arnzneistoff |
DE4424713A1 (de) * | 1994-07-13 | 1996-01-18 | Boehringer Ingelheim Kg | Substituierte Benzamidine, ihre Herstellung und Verwendung als Arnzneistoffe |
DE19546452A1 (de) * | 1995-12-13 | 1997-06-19 | Boehringer Ingelheim Kg | Neue Phenylamidinderivate, Verfahren zu ihrer Herstelung und ihre Verwendung als Arzneimittel |
-
1996
- 1996-09-10 DE DE19636689A patent/DE19636689A1/de not_active Withdrawn
-
1997
- 1997-09-08 ZA ZA9708045A patent/ZA978045B/xx unknown
- 1997-09-09 TW TW086113036A patent/TW378200B/zh not_active IP Right Cessation
- 1997-09-09 JP JP51324398A patent/JP4150427B2/ja not_active Expired - Fee Related
- 1997-09-09 CZ CZ0082299A patent/CZ297252B6/cs not_active IP Right Cessation
- 1997-09-09 EE EEP199900086A patent/EE04431B1/xx not_active IP Right Cessation
- 1997-09-09 AT AT97942007T patent/ATE224363T1/de active
- 1997-09-09 US US09/242,389 patent/US6197824B1/en not_active Expired - Lifetime
- 1997-09-09 IL IL12814497A patent/IL128144A/en not_active IP Right Cessation
- 1997-09-09 DK DK97942007T patent/DK0929516T3/da active
- 1997-09-09 WO PCT/EP1997/004921 patent/WO1998011062A1/de active IP Right Grant
- 1997-09-09 CA CA002262566A patent/CA2262566C/en not_active Expired - Fee Related
- 1997-09-09 AT AT02003690T patent/ATE266630T1/de not_active IP Right Cessation
- 1997-09-09 EP EP97942007A patent/EP0929516B1/de not_active Expired - Lifetime
- 1997-09-09 HU HU9904367A patent/HUP9904367A3/hu unknown
- 1997-09-09 EA EA199900279A patent/EA003245B1/ru not_active IP Right Cessation
- 1997-09-09 KR KR1019997001964A patent/KR20000036005A/ko not_active Application Discontinuation
- 1997-09-09 AU AU43838/97A patent/AU727900B2/en not_active Ceased
- 1997-09-09 BR BR9712816-3A patent/BR9712816A/pt not_active IP Right Cessation
- 1997-09-09 CO CO97052335A patent/CO4900032A1/es unknown
- 1997-09-09 ES ES97942007T patent/ES2184131T3/es not_active Expired - Lifetime
- 1997-09-09 DE DE59711625T patent/DE59711625D1/de not_active Expired - Lifetime
- 1997-09-09 CN CN97197748A patent/CN1104412C/zh not_active Expired - Fee Related
- 1997-09-09 UA UA99042008A patent/UA60315C2/uk unknown
- 1997-09-09 PT PT97942007T patent/PT929516E/pt unknown
- 1997-09-09 TR TR1999/00501T patent/TR199900501T2/xx unknown
- 1997-09-09 DE DE59708278T patent/DE59708278D1/de not_active Expired - Lifetime
- 1997-09-09 PL PL33213697A patent/PL188012B1/pl not_active IP Right Cessation
- 1997-09-09 NZ NZ334895A patent/NZ334895A/xx not_active IP Right Cessation
- 1997-09-09 EP EP02003690A patent/EP1203764B1/de not_active Expired - Lifetime
- 1997-09-09 SK SK296-99A patent/SK282432B6/sk not_active IP Right Cessation
- 1997-09-10 AR ARP970104148A patent/AR009741A1/es active IP Right Grant
-
1999
- 1999-03-01 BG BG103219A patent/BG63938B1/bg active Active
- 1999-03-09 NO NO19991131A patent/NO312239B1/no not_active IP Right Cessation
- 1999-12-02 HK HK99105613A patent/HK1020564A1/xx not_active IP Right Cessation
-
2000
- 2000-12-01 US US09/728,856 patent/US6265612B1/en not_active Expired - Lifetime
-
2008
- 2008-04-16 JP JP2008107036A patent/JP4288299B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001504087A (ja) | Ltb4―アンタゴニスト活性を有するベンズアミド誘導体及びその医薬としての使用 | |
JP2006511596A (ja) | β−2アゴニストとしてのインドール誘導体 | |
KR900001214B1 (ko) | 1-아릴옥시-2,3,4,5-테트라하이드로-3-벤즈아제핀의 제조방법 | |
JPH0623197B2 (ja) | インドール誘導体 | |
CN101273043A (zh) | 用作促肾上腺皮质激素释放因子(CRF)受体拮抗剂的吡唑并[1,5-a]嘧啶基衍生物 | |
US7410987B2 (en) | Method for treating pain or pruritis by administering κ-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative | |
JPH0542435B2 (ja) | ||
JPH10502646A (ja) | 新規化合物、その製造及びその薬学組成物中での利用 | |
JPH0567150B2 (ja) | ||
CA3047023C (en) | Class of bifunctional compounds with quaternary ammonium salt structure | |
LU85999A1 (fr) | Nouvelles isoindolinylalcoylpiperazines | |
JPS5919116B2 (ja) | 複素環式化合物の製造法 | |
JP4049826B2 (ja) | 新規ベンジルアミン誘導体及びフェニルエチルアミン誘導体、それらの製造方法及び医薬組成物としての使用 | |
JP7194828B2 (ja) | コリダルミンの結晶性塩 | |
WO2001094311A1 (fr) | Cytoprotecteurs | |
RU2802964C2 (ru) | Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида | |
JPH0466568A (ja) | 中枢性抗酸化剤化合物 | |
JP4428900B2 (ja) | 新規ltb4拮抗薬、その調製方法及び医薬組成物としてその使用 | |
JP2002522411A (ja) | 新規フェニルエチルアミン誘導体、その製造方法及びその医薬組成物としての使用 | |
JP2559596B2 (ja) | オキサゾリン誘導体 | |
WO1994011363A1 (en) | 2-alkoxy-5,6,7,8-tetrahydroquinoxaline derivative, process for producing the same, and use thereof | |
JPH0219367A (ja) | gem―ジメチル置換二環式化合物、該化合物を含有するカリウム保存性利尿調剤および該化合物の製造方法 | |
MXPA99001797A (en) | Benzamidine derivatives and the use thereof as medicaments with ltb4-antagonistic effect | |
JPS6022711B2 (ja) | トランス−デカハイドロキノリン誘導体,その製造法,及びそれを含む医薬 | |
JPH0641461B2 (ja) | 3−アミノ−2,3−ジヒドロ−1−ベンゾキセピン化合物、その製造法及び該化合物を含有する、抗抑圧作用を有する医薬調剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040909 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071016 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071214 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080416 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20080416 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080610 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080630 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110704 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110704 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120704 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120704 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130704 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |